Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1238-1244

  Cheng, Hsueh Tsen ^a   Hung, Wen Chun ^b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Histone deacetylase; Sp1; Suberoylanilide hydroxamic acid; Vascular endothelial growth factor C

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITHRAMYCIN; TRANSCRIPTION FACTOR; VASCULOTROPIN C; VORINOSTAT;

ANGIOGENESIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84872779585     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2188     Document Type: Article

References (37)

1. Sarkies P and Sale JE: Cellular epigenetic stability and cancer. Trends Genet 28: 118-127, 2012.
2. Esteller M and Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196: 1-7, 2002.
3. Kouzarides T: Chromatin modifications and their function. Cell 128: 693-705, 2007. (Pubitemid 46273577)
4. Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.
5. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001. (Pubitemid 32298546)
6. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001. (Pubitemid 33741894)
8. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. (Pubitemid 43054973)
9. Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90, 2007. (Pubitemid 46087907)
10. Duvic M and Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120, 2007. (Pubitemid 47074165)
11. Peart MJ, Tainton KM, Ruefli AA, et al: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003. (Pubitemid 36951018)
12. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004. (Pubitemid 40054069)
13. F1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004. (Pubitemid 38182673)
14. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545, 2004. (Pubitemid 38084672)
15. Khan AN and Tomasi TB: Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 40: 164-178, 2008. (Pubitemid 351912834)
16. Ogbomo H, Michaelis M, Kreuter J, Doerr HW and Cinatl J Jr: Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 581: 1317-1322, 2007. (Pubitemid 46452605)
17. Deroanne C F, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002. (Pubitemid 34123805)
18. Alitalo K, Tammela T and Petrova TV: Lymphangiogenesis in development and human disease. Nature 438: 946-953, 2005. (Pubitemid 43093960)
19. Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-Cmediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001. (Pubitemid 32167632)
20. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S and Ristamaki R: Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63: 1920-1926, 2003. (Pubitemid 36460859)
21. Dadras SS, Paul T, Bertoncini J, et al: Tumor lymphangiogenesis: a novel prognostic indaicator for cutaneous melanoma metastasis and survival. Am J Pathol 162: 1951-1960, 2003. (Pubitemid 36613052)
22. Valtola R, Salven P, Heikkila P, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390, 1999. (Pubitemid 29226433)
23. Wang CA, Jedlicka P, Patrick AN, et al: Six1 induces lymphan-giogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest 122: 1895-1906, 2012.
24. Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001. (Pubitemid 32148486)
25. Flaherty KT: Sorafenib in renal cell carcinoma. Clin Cancer Res 13: S747-S752, 2007.
26. Hanrahan EO and Heymach JV: Vascular endothelial growth factor receptor tyrosine kinase inhibitors Vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13: S4617-S4622, 2007.
27. Jimenez X, Lu D, Brennan L, et al: A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 4: 427-434, 2005. (Pubitemid 40443927)
28. Roberts N, Kloos B, Cassella M, et al: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66: 2650-2657, 2006.
29. McDonald DM: New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering. Cancer Cell 18: 541-543, 2010.
30. Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D and Detmar M: Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS One 5: e11941, 2010.
31. Chilov D, Kukk E, Taira S, et al: Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 272: 25176-25183, 1997. (Pubitemid 27415703)
32. Li L and Davie JR: The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275-283, 2010.
33. Wang L, Wei D, Huang S, et al: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003. (Pubitemid 38031822)
34. Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448, 2005. (Pubitemid 41540621)
35. Hung JJ, Wang YT and Chang WC: Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26: 1770-1785, 2006.
36. Wang SA, Chuang JY, Yeh SH, et al: Heat shock protein 90 is important for Sp1 stability during mitosis. J Mol Biol 387: 1106-1119, 2009.
37. Li D, Marchenko ND and Moll UM: SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 19: 1268-1276, 2012.